
Scientists find that the bacteria behind the plague evolved to be less deadly
The first plague pandemic struck in the 500s and lasted for around 200 years.
The Black Death began in the mid-1300s. It was the deadliest pandemic in human history. It killed up to half of the people in Europe, western Asia and Africa, with outbreaks continuing for centuries.
The third plague pandemic broke out in China in the 1850s and continues today, with some cases still being recorded in parts of sub-Saharan Africa.
'It's important to know how these outbreaks spread,' said Javier Pizarro-Cerda. He is a microbiologist at France's Pasteur Institute and co-author of a study published in May.
Pizarro-Cerda and his team studied Yersinia pestis, the bacteria that cause the plague. They looked at samples from every time the pandemic happened.
In all three cases, the bacteria evolved to become weaker and less deadly. By causing less severe infections, the bacteria likely made the pandemics last longer, giving them more opportunity to spread from person to person.
The researchers confirmed this theory by infecting rats with recent plague samples. They found that if the plague was less harmful, the rats stayed sick for a longer time.
While antibiotics can now fight off the plague, the research could help us understand how other pandemics might evolve. This will allow scientists to come up with better ways to protect humans from future plagues.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


South China Morning Post
an hour ago
- South China Morning Post
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRS-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The GSK corporate flag next to a Chinese national flag outside its office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.


South China Morning Post
2 hours ago
- South China Morning Post
Why some Chinese students are skipping elite universities amid job market fears
After underperforming in China's national college entrance exam in June, Lu Jie was accepted into a computer science and technology programme earlier this month at a lesser-known polytechnic university in central China's Hunan province. 'Good schools had too many applicants for this major, so I had to choose a lower-ranked one to pursue it,' Lu said. The results for the exam, better known as the gaokao , have been released over the past two weeks – marking a life-changing moment for students like Lu. Now more than ever, students are opting for majors with strong job prospects over prestigious universities. A focus on immediate employability and job security is eclipsing long-term aspirations and personal interests. Driving this trend is a growing oversupply of college graduates , intensifying competition in the job market amid a challenging economic climate. Computer science has long been a highly popular major, Lu said, but the rise of artificial intelligence (AI) – widely expected to create new job opportunities – has fuelled even greater demand over the past couple of years.


South China Morning Post
3 hours ago
- South China Morning Post
How Chinese scientists fought for 74 years to build most powerful dam on Earth
In 1951, immediately after Tibet 's liberation, the Chinese government established the first Tibetan scientific expedition. Advertisement This was the first comprehensive scientific expedition to the Qinghai-Tibet Plateau. More than 50 researchers, equipped with barometers, compasses and other basic instruments, accompanied the army on their pioneering quest. It took them nearly three years to complete the expedition from the Jinsha River in the east to Mount Everest in the west, and to the Yarlung Tsangpo River in southern Tibet. A geological map highlighting key mining areas along the route was compiled, complemented by the collection of scientific data on soil, meteorology, hydrology, agriculture, language and history. This marked the beginning of plans for the Yarlung Tsangpo dam . On July 19, Premier Li Qiang announced the launch of the Yarlung Tsangpo River downstream hydropower project during its groundbreaking ceremony in the Tibetan city of Nyingchi. Advertisement